Using brain charts that map structural changes in the brain across the human lifespan, Planche et al. estimate the neurodegenerative trajectories of the three major genetic forms of frontotemporal lobar degeneration. tinyurl.com/2s3uhdpw

I’m very happy 🥳 to share our new collaborative work, just published in Brain!🧠 academic.oup.com/brain/advanc...

📰 New article published in NPJ Parkinson's Disease: "Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques" 🧠 ✒️ By M. Darricau, ML Arotçarena, @benjamindehay.bsky.social, E. Bezard and @vincentplanche.bsky.social 📌 For more: www.nature.com/articles/s41...

am pleased to share our letter, highlighting that the science does not yet support regulatory approval of amyloid-targeting therapies for AD based solely on biomarker evidence. alz-journals.onlinelibrary.wiley.com/doi/full/10....

I'm delighted to share the new work by Morgane DARRICAU, just published in NPJ Parkinson's Disease! Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques www.nature.com/articles/s41...

📰 Retrouvez dans @sudouest.fr les travaux de @vincentplanche.bsky.social @imn-bordeaux.bsky.social et praticien hospitalier @chu-bordeaux.fr , sur le diagnostic de la maladie d'Alzheimer et sa précision, encore perfectible : www.sudouest.fr/giro...

[#PRESSE]"Maladie d’Alzheimer ce neurologue bordelais veut rendre son diagnostic plus précis" avec le Dr Vincent Planche neurologue au @chu-bordeaux.fr enseignant chercheur qui travaille sur la maladie d'#Alzheimer @sudouest.fr www.sudouest.fr/gironde/bord... @univbordeaux.bsky.social @inserm.fr

Lien vers le communiqué de presse "vers la définition d’un cadre d’utilisation des biomarqueurs sanguins de la maladie d’Alzheimer en pratique clinique" : www.chu-bordeaux.fr/Espace-m%C3%...

Interpreting p-tau-17 results depends on characterizing the clinical phenotype. Positive predictive value in those w/ subjective cognitive impairment was only 60%. It was 90% in those with MCI & a typical Alzheimer phenotype. Important to consider before widespread use of blood-based biomarkers.

Just out in JAMA Neurol blood biomarkers are powerful—but without cognitive phenotyping, we risk more noise than signal. Plasma p-tau217 needs clinical context or we’ll end up in a false-positive factory! Clinico-biological AD is a reality! 👉🏻 jamanetwork.com/journals/jam... bsky.app/profile/vinc...

Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...

1/ NEW: Lecanemab in France The French Federation of Memory Clinics just released its appropriate use recommendations for #Lecanemab in early #Alzheimers. What’s new? How does it compare to U.S. guidelines? A thread 🧵⬇️ www.sciencedirect.com/science/arti...

AD and PD, same battle! Biology, yes, but not in isolation from clinical practice! Happy to share David Bendetowicz paper: Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease journals.sagepub.com/doi/10.1177/...

Should amyloid-lowering therapies be approved based on biomarker evidence alone? With @vincentplanche.bsky.social we argue for prioritizing clinical endpoints over unvalidated surrogates like amyloid load in AD trials. Read our full critique on AlzForum: www.alzforum.org/news/researc...

There are many reasons why the suggestion to abandon examining our patients in behavioral neurology is a bad idea. One that is often overlooked regarding bedside cognitive screening, is that it allows the family to appreciate the level of mental functioning. #endalz pn.bmj.com/content/earl...

The interpretation of blood tests in terms of predictive values depends on the pre-test probability of being amyloid-positive, and therefore on the clinical context. So clinic first! See @suzanneeschindler.bsky.social paper for the global CEO initiative: www.nature.com/articles/s41...